The FDA has given approval to Gimoti (metoclopramide, Evoke Pharma), the first nasally administered medication for the treatment of adults with symptoms of recurrent diabetic gastroparesis.
“Patients with gastroparesis suffer from characteristic symptoms such as nausea, abdominal pain, bloating, early satiety as well as vomiting which can be severe and debilitating. These patients often have erratic absorption of orally administered drugs due to delayed gastric emptying,” Henry